以下文章来源于浮游若梦 ，作者浮游若梦

【导语】本期推荐的是来自甘肃中医药大学中药学专业李越峰教授指导的博士研究生张育贵为第一作者、王彦钧和辛二旦为共同第一作者在中科院2区期刊Journal of Ethnopharmacology (IF: 5.4）上近期发表的一篇文章：大胆使用简单网络药理学和实验验证揭示了甘肃道地药材红芪与莪术配伍后抗结肠癌的机制。

【期刊简介】Journal of Ethnopharmacology （民族药理学）2023年IF: 5.4, 中科院分区信息如下：

（来自letpub：https://www.letpub.com.cn/）

Aims & Scope: The Journal of Ethnopharmacology is the Official Journal of the International Society for Ethnopharmacology. The journal is dedicated to the exchange of information and understandings about people's use of plants, fungi, animals, microorganisms and minerals and their biological and pharmacological effects based on the principles established through international conventions.

The Journal of Ethnopharmacology publishes original articles concerned with the observation and experimental investigation of the biological activities of plant and animal substances used in the traditional medicine of past and present cultures, which document indigenous medical knowledge, study indigenous medicines in order to contribute in the long-run to improved health care in the regions of study, and which report on pharmacologically unique principles from existing indigenous remedies.

The journal will particularly welcome interdisciplinary papers with an ethnopharmacological, an ethnobotanical or an ethnochemical approach to the study of indigenous drugs. It is imperative that experimental studies are aligned and related to the traditional use(s).

Furthermore:

Reports of anthropological and ethnobotanical field studies fall within the journal's scope.

Studies involving pharmacological and toxicological mechanisms of action are especially welcome.

Clinical studies on efficacy will be considered if contributing to the understanding of specific ethnopharmacological problems.

The journal welcomes review articles in the above-mentioned fields especially those highlighting the multi-disciplinary nature of ethnopharmacology.

【文章题目信息】

【图文摘要】

【前言】

黄芪（AR）-莪术（临床常用其醋制品，VPCR）药对源于中医学典籍《医学衷中参西录》，被用于治疗胃肠道疾病，如结肠炎相关性结肠直肠癌（CAC）。与 AR 同科异属的红芪（HR）可与AR替换使用于临床配伍治疗疾病，在与 VPCR 配伍治疗 CAC 时，传统上被用作 AR 的替代品。然而，HR代替AR配伍VPCR 治疗CAC 的最佳配伍比例及其内在机制仍不清楚。

【亮点】

1. HR-VPCR is effective in mitigating the progression of CAC.

2. A 4:1 ratio is optimal for HR-VPCR to ameliorate CAC.

3. HR-VPCR inhibits the inflammatory processes associated with CAC.

4. HR-VPCR alleviates CAC by improving intestinal permeability and regulating the PI3K-AKT pathway

【结果】

1. 不同配伍比例HR-VPCR对CAC小鼠的不同治疗效果

2. 不同配伍比例HR-VPCR对CAC小鼠干预17周后的结肠代表性

3. 不同配伍比例HR-VPCR对CAC小鼠脏器指数的影响

4. 不同配伍比例HR-VPCR对CAC小鼠结肠病变及血清验证因子的影响

5. 不同配伍比例HR-VPCR对CAC小鼠结肠中肿瘤标志物的调控作用

6. 不同配伍比例HR-VPCR对CAC小鼠肠粘膜通透性的影响

7. 数学模型优选最佳配伍比例

由加权及贴近度结果可知：不同配伍HR-VPCR改善 CAC的最佳配伍比为4:1。

8. HR-VPCR（4:1）的HPLC分析

9. HR-VPCR（4:1）治疗CAC的网络药理学分析

10. 实验验证

11. 机制图

【结论】

综上，本研究对HR-VPCR的13个不同配伍比例在CAC中的的治疗效果进行了全面评估和比较，最终确定4:1为HR-VPCR治疗CAC的最佳配伍比例。此外，研究阐明了HR-VPCR治疗后可缓解肠道炎症、改善肠道通透性和调节PI3K-AKT信号通路以防治CAC的潜在机制。

转自：“如沐风科研”微信公众号

如有侵权，请联系本站删除！